News | 01.22.20
Consensus Statement Published on the Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease
January 22, 2020—A consensus statement from the American College of Radiology and the National Kidney Foundation addresses the use of intravenous iodinated contrast media in patients with kidney disease.
News | 11.14.19
European Societies Publish Consensus Document on Follow-Up After Revascularization for PAD
November 14, 2019—A consensus document from European societies on the follow-up of patients after revascularization for peripheral artery disease (PAD) was published by Maarit Venermo, MD, et al in the European Journal of Vascular and Endovascular Surgery (2019;58:641–653).
News | 09.29.19
REMEDIAL III Shows UFR-Guided Hydration Reduces Risk of Contrast-Induced Kidney Injury in High-Risk Patients
September 29, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the REMEDIAL III trial were presented by Carlo Briguori, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 06.17.19
Merit Medical Acquires Brightwater Medical
June 17, 2019—Merit Medical Systems, Inc. announced that it has acquired Brightwater Medical, Inc. The transaction consists of a $35 million upfront payment and potential earn-out payments of up to $15 million based on receipt of CE Mark approval and achievement of future sales targets.
News | 05.22.19
Studies Support Medtronic's Renal Denervation System in High-Risk Hypertensive Patients
May 22, 2019—Medtronic announced that late-breaking clinical data from a physician-sponsored clinical trial using the company's Symplicity renal denervation (RDN) system were presented at EuroPCR held May 21–24 in Paris, France.
News | 03.20.19
News | 02.13.19
BD's WavelinQ 4-F endoAVF System Receives FDA 510(k) Clearance
February 13, 2019—BD (Becton, Dickinson and Company) announced that it has received FDA 510(k) clearance for its WavelinQ 4-F endoAVF system, which allows the creation of an arteriovenous (AV) fistula in either the ulnar artery and ulnar vein or the radial artery and radial vein in patients with end-stage renal disease (ESRD) on hemodialysis.
News | 01.16.19
Study Evaluates Strength of Evidence Underlying the AHA/ACC Guidelines on Treating Peripheral Vascular Disease
January 16, 2019—Findings from a study evaluating the evidence base supporting the American Heart Association (AHA)/American College of Cardiology (ACC) guidelines on peripheral vascular interventions (PVIs) were published by Partha Sardar, MD, et al online in Circulation: Cardiovascular Interventions. The investigators concluded that there is significant variation in the level of evidence (LOE) supporting various PVIs in the current guidelines.
News | 01.16.19
New Appropriate Use Criteria Address Peripheral Artery Interventions
January 16, 2019—The American College of Cardiology (ACC) announced that the "2018 Appropriate Use Criteria for Peripheral Artery Intervention" document was published by Steven R. Bailey, MD, et al online in Journal of the American College of Cardiology.
News | 11.08.18
FDA Approves SPYRAL HTN-ON MED Study of Medtronic's Symplicity Spyral RDN System
November 8, 2018—Medtronic announced FDA approval to begin a clinical trial to evaluate the company's Symplicity Spyral renal denervation (RDN) system in patients with uncontrolled blood pressure taking multiple antihypertensive medications.
News | 08.09.18
News | 05.30.18
Quality-of-Life and Economic Data Presented for TVA Medical's everlinQ endoAVF System
May 30, 2018—TVA Medical, Inc. announced that findings from a health care analysis show that the company's catheter-based endovascular system for creating hemodialysis access offers quality-of-life benefits and cost savings compared with the traditional surgical approach in patients with end-stage renal disease (ESRD).
News | 05.22.18
Financing Will Support Launch of Med Alliance's Selution DCB
May 22, 2018—Med Alliance announced that it has received $22 million in financing to be used to fund European commercialization, achieve United States regulatory approval, and support global clinical programs for the company's Selution drug-coated balloon (DCB).
News | 04.09.18
FDA Approves Medtronic's Pivotal Trial to Evaluate Renal Denervation to Treat Hypertension
April 9, 2018—Medtronic announced US Food and Drug Administration approval to begin an investigational device exemption pivotal trial to evaluate the company's Symplicity Spyral renal denervation system in patients with hypertension.
News | 04.02.18
Cook Begins Relaunch of Beacon Tip Catheter Line
April 2, 2018—Cook Medical has begun reintroducing its line of Beacon Tip angiographic catheters, starting in the United States and Canada with the 5-F Beacon Tip Torcon NB Advantage line. Certain lots of the workhorse radiopaque-tipped catheter line were voluntarily recalled starting in 2015, and in 2016, Cook announced that the entire product line was being pulled due to tip splitting and/or fracture.
News | 01.19.18
FDA Seeks to Strengthen Public Warnings and Recall Notifications; CDRH Outlines Strategic Priorities
January 18, 2018—US Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, issued a statement on the agency's new policy steps for strengthening public warnings and notifications of recalls.
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in Europe.